Vaxcyte (PCVX) Profit After Tax (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Profit After Tax of -$320.6 million for Q1 2026, down 127.85% year-over-year from $1.2 billion in Q1 2025, and down 30.07% quarter-over-quarter from -$246.5 million in Q4 2025.
Vaxcyte (PCVX) Profit After Tax (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Profit After Tax for 8 consecutive years, with -$320.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 127.85% year-over-year to -$320.6 million; the TTM figure through Mar 2026 stood at -$946.5 million (down 84.28% YoY), while the FY2025 annual figure was -$766.6 million, down 63.82% from the prior year.
- Profit After Tax eased to -$320.6 million in Q1 2026 per PCVX's latest filing, from -$246.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$39.0 million in Q1 2022 and bottomed at -$320.6 million in Q1 2026.
- Historically, Profit After Tax has averaged -$128.3 million across 5 years, with a median of -$103.1 million in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax slumped 173.26% — and 2024, when it increased 21.96%.
- Vaxcyte's Profit After Tax stood at -$78.0 million in 2022, then tumbled by 131.65% to -$180.8 million in 2023, then gained by 21.96% to -$141.1 million in 2024, then sank by 74.71% to -$246.5 million in 2025, then sank by 30.07% to -$320.6 million in 2026.
- Business Quant data shows PCVX's Profit After Tax at -$320.6 million in Q1 2026, -$246.5 million in Q4 2025, and -$212.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | -285.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -285.01 Mn |
| Mar 31, 2026 | -320.62 Mn |
| Dec 31, 2025 | -246.51 Mn |
| Sep 30, 2025 | -212.83 Mn |
| Jun 30, 2025 | -166.57 Mn |
| Mar 31, 2025 | -140.72 Mn |
| Dec 31, 2024 | -141.09 Mn |
| Sep 30, 2024 | -103.12 Mn |
| Jun 30, 2024 | -128.70 Mn |
| Mar 31, 2024 | -95.02 Mn |
| Dec 31, 2023 | -180.80 Mn |
| Sep 30, 2023 | -92.66 Mn |
| Jun 30, 2023 | -68.34 Mn |
| Mar 31, 2023 | -60.46 Mn |
| Dec 31, 2022 | -78.05 Mn |
| Sep 30, 2022 | -57.92 Mn |
| Jun 30, 2022 | -48.53 Mn |
| Mar 31, 2022 | -38.99 Mn |
| Dec 31, 2021 | -28.56 Mn |
| Sep 30, 2021 | -26.62 Mn |